Mechanisms of natural gene therapy in dystrophic epidermolysis bullosa

Journal of Investigative Dermatology

Volumn 134, Issue 8, 2014, Pages 2097-2104

  Kiritsi, Dimitra ^a   Garcia, Marta ^b   Brander, Renske ^a,c   Has, Cristina ^a   Meijer, Rowdy ^d   Jose Escámez, Maria ^b   Kohlhase, Jürgen ^e   Van Den Akker, Peter C ^c   Scheffer, Hans ^d   Jonkman, Marcel F ^c   Del Rio, Marcela ^b   Bruckner Tuderman, Leena ^a,e   Pasmooij, Anna M G ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSIDAD CARLOS III DE MADRID   (Spain)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COL7A1 PROTEIN; COLLAGEN TYPE 7; IMMUNOGLOBULIN E; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLELE; ALTERNATIVE RNA SPLICING; ARTICLE; ATOPIC DERMATITIS; BLISTER; CELL BASED GENE THERAPY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CODON; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; DISEASE PREDISPOSITION; DISEASE SEVERITY; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EXON; FIBROBLAST; FRAMESHIFT MUTATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; INTRON; KERATINOCYTE; LASER DISSECTION MICROSCOPY; LASER MICROSCOPY; LYMPHOCYTE; MIDDLE AGED; MISSENSE MUTATION; MITOTIC RECOMBINATION; MOSAICISM; MUCOSA; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERTANT; SCAR FORMATION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BIOPSY; TRANSDERMAL PATCH; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; COLLAGEN TYPE VII; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC THERAPY; HUMANS; MIDDLE AGED; MOSAICISM; MUTATION;

EID: 84904464829     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.118     Document Type: Article

References (27)

1. Almaani N, Nagy N, Liu L et al. (2010) Revertant mosaicism in recessive dystrophic epidermolysis bullosa. J Invest Dermatol 130:1937-40
2. Bruckner-Tuderman L, Has C (2012) Molecular heterogeneity of blistering disorders: The paradigm of epidermolysis bullosa. J Invest Dermatol 132:E2-5
3. Choate KA, Lu Y, Zhou J et al. (2010) Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10. Science 330:94-7
4. Chung HJ, Uitto J (2010) Type VII collagen: The anchoring fibril protein at fault in dystrophic epidermolysis bullosa. Dermatol Clin 28:93-105
5. Csikos M, Szocs HI, Laszik A et al. (2005) High frequency of the 425A-4G splice-site mutation and novel mutations of the COL7A1 gene in central Europe: Significance for future mutation detection strategies in dystrophic epidermolysis bullosa. Br J Dermatol 152:879-86
6. Davis BR, Candotti F (2010) Genetics. Mosaicism-switch or spectrum? Science 330:46-7
7. Escamez MJ, Garcia M, Cuadrado-Corrales N et al. (2010) The first COL7A1 mutation survey in a large Spanish dystrophic epidermolysis bullosa cohort: C.6527insC disclosed as an unusually recurrent mutation. Br J Dermatol 163:155-61
8. Fine JD, Eady RA, Bauer EA et al. (2008) The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 58:931-50
9. Gedde-Dahl T Jr. (1971) Epidermolysis Bullosa: A Clinical, Genetic and Epidemiological Study. Spinal cord injury. Clinical outcomes from the model systems. The Johns Hopkins Press: Baltimore, pp49-51
10. Ghazizadeh S, Taichman LB (2005) Organization of stem cells and their progeny in human epidermis. J Invest Dermatol 124:367-72
11. Gostynski A, Deviaene FC, Pasmooij AM et al. (2009) Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy. Br J Dermatol 161:444-7
12. Intong LR, Murrell DF (2012) Inherited epidermolysis bullosa: New diagnostic criteria and classification. Clin Dermatol 30:70-7
13. Itoh M, Kiuru M, Cairo MS et al. (2011) Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc Natl Acad Sci USA 108:8797-802
14. Jongmans MC, Verwiel ET, Heijdra Y et al. (2012) Revertant somatic mosaicism by mitotic recombination in dyskeratosis congenita. Am J Hum Genet 90:426-33
15. Jonkman MF, Pasmooij AM (2012) Realm of revertant mosaicism expanding. J Invest Dermatol 132:514-6
16. Kern JS, Gruninger G, Imsak R et al. (2009) Forty-two novel COL7A1 mutations and the role of a frequent single nucleotide polymorphism in the MMP1 promoter in modulation of disease severity in a large European dystrophic epidermolysis bullosa cohort. Br J Dermatol 161:1089-97
17. Kern JS, Kohlhase J, Bruckner-Tuderman L et al. (2006) Expanding the COL7A1 mutation database: Novel and recurrent mutations and unusual genotypephenotype constellations in 41 patients with dystrophic epidermolysis bullosa. J Invest Dermatol 126:1006-12
18. Kiritsi D, He Y, Pasmooij AM et al. (2012) Revertant mosaicism in a human skin fragility disorder results from slipped mispairing and mitotic recombination. J Clin Invest 122:1742-6
19. Kiritsi D, Kern JS, Schumann H et al. (2011) Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa. J Med Genet 48:450-7
20. Pasmooij AM, Garcia M, Escamez MJ et al. (2010) Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 130:2407-11
21. Pasmooij AM, Nijenhuis M, Brander R et al. (2012) Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations. J Invest Dermatol 132:1374-83
22. Pasmooij AM, Pas HH, Bolling MC et al. (2007) Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3. J Clin Invest 117:1240-8
23. Pasmooij AM, Pas HH, Deviaene FC et al. (2005) Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. Am J Hum Genet 77:727-40
24. Tolar J, Xia L, Riddle MJ et al. (2011) Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 131:848-56
25. Tolar J, McGrath JA, Xia L et al. (2013) Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. J Invest Dermatol; e-pub ahead of print, doi:10.1038/jid.2013.523
26. Uitto J (2011) Regenerative medicine for skin diseases: IPS cells to the rescue. J Invest Dermatol 131:812-4
27. van den Akker PC, Nijenhuis M, Meijer G et al. (2012) Natural gene therapy in dystrophic epidermolysis bullosa. Arch Dermatol 148:213-6